HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Onco News
Farmaexplorer.it

Search results for "Kyprolis"

Results from a study published in Blood, the Journal of the American Society of Hematology ( ASH ), have demonstrated that inclusion of Carfilzomib ( Kyprolis ), a novel targeted therapy for multiple ...


The Food and Drug Administration ( FDA ) has granted accelerated approval of Kyprolis ( Carfilzomib ) for injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myelo ...


The medical journal Leukemia has published results from the Phase 2 trial known as PX-171-005, an open-label, multicenter clinical trial evaluating Kyprolis ( Carfilzomib ) for injection in patients w ...


Carfilzomib ( Kyprolis ) is a selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In an open-label, single-arm phase 2 study ( PX-171-003- ...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for injection in combination with low-dose Dexamethasone versus Bortezomi ...


Data from a secondary analysis of the pivotal phase 3 ASPIRE trial that showed Carfilzomib ( Kyprolis ) for injection in combination with Lenalidomide ( Revlimid ) and Dexamethasone ( KRd) improved pr ...


Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were presented. The study met the key secondary endpoint of overall survival, demons ...